Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

The Global Blood Collection Devices Market to Register Incremental Growth at a CAGR of ~7% by 2027 | DelveInsight

Published

on

<!– Name:DistributionId Value:8777214 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:1160fbac-bfc5-437c-a68b-2eec73b0e173 –>

New York, USA, Feb. 27, 2023 (GLOBE NEWSWIRE) — The Global Blood Collection Devices Market to Register Incremental Growth at a CAGR of ~7% by 2027 | DelveInsight

The blood collection devices market is expected to prosper as a result of factors such as an increase in diagnostic tests due to the rising prevalence of infectious diseases such as COVID-19, malaria, and others, increased health awareness, an increase in blood transfusion procedures, and a growing focus on improving the safety and usability of blood collection devices for end users (2022–2027).

DelveInsight’s Blood Collection Devices Market Insights report provides the current and forecast market analysis, individual leading blood collection devices companies’ market shares, challenges, blood collection devices market drivers, barriers, and trends, and key blood collection devices companies in the market.

Key Takeaways from the Blood Collection Devices Market Report

  • As per DelveInsight estimates, North America is anticipated to dominate the global blood collection devices market during the forecast period. 
  • Notable blood collection devices companies such as BD, Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, Nipro Europe Group Companies, FL MEDICAL s.r.l., Greiner Bio-One International GmbH, Cardinal Health, SARSTEDT AG & Co. KG, Thermo Fisher Scientific Inc., ICU Medical, Grifols, S.A, CML Biotech, INTERNATIONAL SCIENTIFIC SUPPLIES LTD, Demophorius Healthcare LTD, AB MEDICAL Co., Ltd., Trajan Scientific and Medical, Macopharma, VOGT MEDICAL, Ljungberg & Kögel AB, and several others are currently operating in the blood collection devices market.
  • In October 2022, Sol-Millennium Inc., a medical device company and innovator in medication delivery and specimen collection, announced that it had received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Sol-Guard® Safety Pull Button Blood Collection Set, the company’s rapidly expanding blood collection portfolio.
  • In October 2022, BD (Becton, Dickinson, and Company), a leading global medical technology company, and Magnolia Medical Technologies, Inc. announced a co-exclusive commercial agreement today to assist U.S. hospitals in reducing blood culture contamination, which will help improve testing accuracy and, ultimately, clinical outcomes.
  • In September 2022, Tasso announced that the FDA had cleared its Tasso+ lancet blood collection system as a Class II medical device.
  • In March 2022, Terumo Blood and Cell Technologies, a medical device company, received U.S. Food and Drug Administration (FDA) approval for its new plasma collection system named Rika Plasma Donation System (Rika), which is a next-generation automated technology with safety features to minimize operator errors and collects plasma in 35 minutes or less.
  • In February 2022, Abacus dx announced the launch of RNA Complete BCT™, which is the newest addition to Streck’s trusted blood collection tube portfolio. The tube allows for convenient sample collection, transport, and storage.

To read more about the latest highlights related to the blood collection devices market, get a snapshot of the key highlights entailed in the Global Blood Collection Devices Market Report

Blood Collection Devices Overview

Blood collection is the process of drawing blood samples from patients before they are tested in a laboratory. It employs what is commonly known as the “order of draw” principle. It counts or examines blood cells, chemicals, proteins, and other substances. It is one of the most common types of lab tests and is frequently performed as part of a routine checkup. The various tests and biochemical assays necessitate different types of sample collection tubes. The recommended procedure is to collect multiple venous and arterial blood samples in a single patient, using a color sequence of withdrawal and its indications based on the Clinical & Laboratory Standards Institute (CLSI). Blood collection devices are medical devices used in the safe and efficient collection, transportation, and storage of blood samples for later diagnostic and treatment purposes.

Blood Collection Devices Market Insights

North America is expected to lead the global blood collection devices market in terms of revenue generation. This can be attributed, among other things, to the presence of a large patient pool associated with cancer and other diseases, an increase in blood transfusion procedures, a highly potent market in terms of product development and launches, and the local presence of key blood collection devices market players.

One of the major factors driving the growth of the North American blood collection devices market is the widespread use of blood collection devices by end users, particularly in the United States, for sample collection in the diagnosis of various diseases.

To know more about why North America is leading the market growth in the blood collection devices market, get a snapshot of the Blood Collection Devices Market Outlook 

Blood Collection Devices Market Dynamics

Among the significant drivers of the blood collection devices market, the rising prevalence of infectious diseases, which necessitates a wide range of blood sample collection and testing, appears to be the most important factor for accelerating the blood collection devices market. Furthermore, rising health awareness will drive up demand for routine health checkups, boosting blood collection devices market growth. Another important factor driving the growth of the blood collection devices market is the steady increase in blood donations.

However, the risk of blood sample contamination during transport and storage and a scarcity of skilled phlebotomists may act as restraints on the growth of the blood collection devices market.

Additionally, the blood collection devices market experienced a brief period of market restraint due to the implementation of lockdown as necessary measures to prevent the spread of COVID-19 infection, which resulted in the suspension of routine diagnostic checkups. Furthermore, during the initial phases of the lockdown, the manufacturing and supply of blood collection devices were hampered, resulting in a further decline in the blood collection devices market. However, as the number of COVID-19 cases increased, so did the demand for blood testing and plasma donation, resulting in a slight improvement in the blood collection devices market.

Moreover, with the resumption of activities such as routine health checkups, tests for other diseases, and others across industries, including the healthcare sector, the blood collection devices market is expected to grow during the forecast period of 2022–2027.

Get a sneak peek at the blood collection devices market dynamics @ Blood Collection Devices Market Dynamics Analysis

Report Metrics Details
Coverage Global
Study Period 2019–2027
Base Year 2021
Blood Collection Devices Market CAGR ~7%
Projected Blood Collection Devices Market Size by 2027 USD 9.25 Billion
Key Blood Collection Devices Companies BD, Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, Nipro Europe Group Companies, FL MEDICAL s.r.l., Greiner Bio-One International GmbH, Cardinal Health, SARSTEDT AG & Co. KG, Thermo Fisher Scientific Inc., ICU Medical, Grifols, S.A, CML Biotech, INTERNATIONAL SCIENTIFIC SUPPLIES LTD, Demophorius Healthcare LTD, AB MEDICAL Co., Ltd., Trajan Scientific and Medical, Macopharma, VOGT MEDICAL, Ljungberg & Kögel AB, among others

Blood Collection Devices Market Assessment

  • Blood Collection Devices Market Segmentation
    • Market Segmentation By Product Type: Blood Collection Tubes (Edta, Heparin, and Others)
    • Market Segmentation By Method: Manual and Automatic
    • Market Segmentation By End User: Hosptials And Clinics, Diagnostic Labs, Blood Banks, and Others
    • Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the blood collection devices market are set to emerge as the trendsetter explore @ Blood Collection Devices Companies 

Table of Contents 

1 Report Introduction
2 Executive summary
3 Regulatory and Patent Analysis
4 Key Factors Analysis
5 Porter’s Five Forces Analysis
6 COVID-19 Impact Analysis on Blood Collection Devices Market
7 Blood Collection Devices Market Layout
8 Global Company Share Analysis – Key 3-5 Companies
9 Blood Collection Devices Market Company and Product Profiles
10 Project Approach
11 About DelveInsight

Interested in knowing the blood collection devices market by 2027? Click to get a snapshot of the Blood Collection Devices Market Trends

Related Reports

Blood Cancer Diagnostics Market

Blood Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key blood cancer diagnostics companies, including BD, Abbott, Agilent Technologies, Inc., Adaptive Biotechnologies, F. Hoffmann-La Roche Ltd., among others.

Blood and Fluid Warming Medical Devices Market

Blood and Fluid Warming Medical Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key blood and fluid warming medical devices companies, including General Electric Company, ICU Medical, Inc., BD, Boston Scientific Corporation, 3M, Barkey, SINO MDT, EMIT CORPORATION, among others.

Hematological Cancer Therapeutics Market

Hematological Cancer Therapeutics Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key hematological cancer therapeutics companies, including Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, among others.

Refractory Multiple Myeloma Market

Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.

Relapsing Refractory Multiple Myeloma Market

Relapsing Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Blogs 

Multiple Myeloma Treatment Market 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Permira to Acquire Majority Position in BioCatch at $1.3bn Valuation

Published

on

permira-to-acquire-majority-position-in-biocatch-at-$1.3bn-valuation

Permira Growth Opportunities Transaction builds on initial minority investment made in early 2023 to acquire a majority position and support BioCatch’s accelerated growth within online fraud detection and financial crime prevention
NEW YORK and TEL AVIV, Israel, May 2, 2024 /PRNewswire/ — BioCatch (the “Company”), the global leader in digital fraud detection and financial crime prevention powered by behavioral biometric intelligence, today announced that Permira Growth Opportunities II (the “Fund”), a fund advised by global private equity firm Permira, has agreed to acquire a majority position in the Company. Alongside the Fund’s investment, existing shareholders Sapphire Ventures and Macquarie Capital will also increase their investments in BioCatch. The transaction is expected to accelerate the Company’s global expansion, advance its innovative product roadmap and support its continued overall growth.

Under the terms of the agreement, the Fund will acquire a majority stake in BioCatch, buying out shares primarily from Bain Capital Tech Opportunities and Maverick Ventures, in a secondary transaction valuing the Company at a total enterprise valuation of $1.3bn.
BioCatch was founded in 2011 – at the dawn of a significant consumer shift from branch to online banking – with a mission to fight fraud and keep users safe in online transactions without disrupting user experience. Today, the Company is a leader in behavioral biometric intelligence and advanced fraud detection, leveraging patented artificial intelligence, data science, and machine learning technology to analyze a user’s cognitive intent and deliver highly accurate insights as to the legitimacy of their identity, motivations, and behavior. In 2023, the Company expanded its mission to include a proactive approach to fighting financial crime with the launch of predictive, behavior-based mule account detection.
As fraud attacks have become increasingly scaled, sophisticated and complex, BioCatch has experienced significant and sustained momentum. Permira, via its growth equity strategy, completed an initial minority investment in the Company in early 2023, a year that BioCatch ultimately finished with 49% ARR growth, whilst also surpassing the $100 million ARR milestone and attaining EBITDA profitability. Today, BioCatch counts more than 190 financial institutions as customers globally, including over 30 of the world’s largest 100 global banks, who use its solutions to fight fraud, facilitate financial crime prevention and decision intelligence sharing, accelerate digital transformation, and grow the value of customer relationships.
Permira brings a growth mindset to BioCatch’s next chapter, with the ability and network to help the Company expand across Continental Europe, where Permira was first established nearly four decades ago. In addition, Permira is excited to back the Company’s exceptional management team and innovative product roadmap, and is committed to further strengthening BioCatch’s global leadership position both organically and inorganically.
“Permira has backed the theme of cybersecurity for several years, and within this, online fraud detection, customer identity and access management markets have become a clear focus. We have tracked BioCatch with enthusiasm for many years, and now having been a shareholder since early 2023, our conviction in the business, its growth potential, its technology leadership, and its management team continues to grow. We’re excited to become the company’s majority shareholder and look forward to a continued successful partnership with Gadi and the BioCatch team as we seek to further accelerate growth and expansion in the years to come,” said Stefan Dziarski, Partner and Co-Head of Permira Growth Opportunities.
Gadi Mazor, CEO of BioCatch, added: “After building a strong partnership with Permira over the last year, we are delighted to welcome them as majority shareholders. The firm’s impressive experience within technology and cybersecurity, combined with their scale, global network, and our close working relationship, has been invaluable since their initial investment. We’re excited to take BioCatch to the next level together. I’d also like to thank Matthew Kinsella from Maverick Ventures and Dewey Awad from Bain Capital for their support over the last four years, which has been key in helping us establish our leadership position in the market.”
“We have had the privilege of partnering with BioCatch over the past four years and worked closely with Gadi and the BioCatch team to develop a long-term strategy to realize the business’s growth potential,” said Dewey Awad, a Partner at Bain Capital. “Together, we drove several key initiatives aimed at augmenting BioCatch’s go-to-market strategy, team, and operations, all with the goal of protecting end-users and their most sensitive transactions. We believe the company is well-positioned to continue its growth journey under Gadi’s leadership and with Permira’s support.”
“At Permira, we are looking to back product-led businesses operating in structurally growing end markets and that have management teams with the ambition to scale and grow their business. We found all of that in BioCatch and were grateful to have the opportunity to make an initial investment in 2023. After a successful first year, we are delighted to take a majority stake in the business as it continues to grow at scale. With the full extent of Permira’s resources and experience at its disposal, we’re excited for what’s to come at BioCatch,” commented Ran Maidan, Senior Adviser and Head of Permira in Israel.
About Permira
Permira is a global investment firm that backs successful businesses with growth ambitions. Founded in 1985, the firm advises funds with total committed capital of approximately €80bn and makes long-term majority and minority investments across two core asset classes, private equity and credit.
The Permira funds have an extensive track record in technology investing, having invested in 50+ companies across SaaS, cybersecurity, digital commerce, fintech and online marketplaces. Permira invested in BioCatch via its Growth Opportunities Fund; its strategy is to back disruptive technology and tech-enabled companies as they scale to the next level. The Permira funds have previously supported and helped scale some of the largest and fastest-growing technology businesses globally, including Genesys, TeamViewer, Zendesk, McAfee, Mimecast, Carta, G2, Sysdig, SonarSource, Mirakl, and others. Permira closed its second Growth Opportunities Fund in December 2021 at $4 billion.
The Permira private equity funds have made approximately 300 private equity investments in four key sectors: Technology, Consumer, Healthcare and Services. Permira employs over 500 people in 15 offices across Europe, the United States and Asia. For more information, visit www.permira.com or follow us on LinkedIn.
About BioCatch
BioCatch stands at the forefront of digital fraud detection, pioneering behavioral biometric intelligence grounded in advanced cognitive science and machine learning. BioCatch analyzes thousands of user interactions to support a digital banking environment where identity, trust, and ease coexist. Today, more than 30 of the world’s largest 100 banks and more than 190 total financial institutions rely on BioCatch Connect™ to combat fraud, facilitate digital transformation, and grow customer relationships.
BioCatch’s Client Innovation Board, an industry-led initiative featuring American Express, Barclays, Citi Ventures, HSBC, and National Australia Bank, collaborates to pioneer creative and innovative ways to leverage customer relationships for fraud prevention. With more than a decade of data analysis, 90 registered patents, and unmatched expertise, BioCatch continues to lead innovation to address future challenges. For more information, visit www.biocatch.com.
Media Contacts
For BioCatch
Mac KingSr. Manager, Corporate Communications, [email protected]+1-206-200-8596
For Permira
James [email protected] +44 774 7006407
Logo – https://mma.prnewswire.com/media/1843699/biocatch_logo_rgb_2x_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/permira-to-acquire-majority-position-in-biocatch-at-1-3bn-valuation-302133942.html

Continue Reading

Artificial Intelligence

JupiterOne and watchTowr announce partnership to protect business critical assets with broad exposure management capabilities

Published

on

jupiterone-and-watchtowr-announce-partnership-to-protect-business-critical-assets-with-broad-exposure-management-capabilities

SINGAPORE, May 2, 2024 /PRNewswire/ — watchTowr, a leader in external attack surface management (EASM) technology and fuelled by watchTowr Labs, a renowned vulnerability R&D capability, has formed a strategic partnership with JupiterOne. JupiterOne is a leader in cyber asset attack surface management (CAASM) technology. This collaboration enables customers to rapidly prioritize emerging threats within their constantly changing environments, focusing on fixing the most critical risks impacting their business, which enables an end-to-end continuous threat exposure management process (CTEM).

Over 28,000 CVE records were published in 2023; a figure that is expected to increase as attackers shorten the time from known vulnerability to exploit, reducing it from weeks to days. JupiterOne and watchTowr’s integrated solution empowers enterprises to discover their most critical and exploitable vulnerabilities, prioritize them with asset context based on business impact and receive an actionable remediation plan to improve security posture.
This partnership enables a complete continuous threat exposure management program, addressing the full spectrum of cyber risk management. The fully integrated solution provides continuous monitoring and assessment of both internal and external digital assets, allowing for prioritization and effective threat mitigation for a business’s most critical assets. “Our partnership with watchTowr is a game-changer” said Forte. “Combining our data aggregation with real-time asset discovery and automated security testing allows us to offer a unique, all-encompassing approach to exposure management.”
Benjamin Harris, CEO, watchTowr, said, “While the number of reported vulnerabilities continues to rise, the vulnerabilities that matter – in mission-critical, key systems – have exploded at an alarming rate. This reality, combined with the significant shift in speed by attackers to weaponize vulnerabilities – the ability to validate exploitability and prioritise actions based on real business risk has never been more vital. We’re excited to join forces with JupiterOne to give security teams around the globe this much-needed end-to-end capability.”
About JupiterOne:
JupiterOne is a cybersecurity startup delivering powerful software solutions to companies across all industries, providing deep insights to cyber assets and the relationships between, empowering security professionals to have true knowledge and ownership of their attack surfaces.
About watchTowr: 
watchTowr is a global cybersecurity technology company, built by former adversaries.
watchTowr’s world-class External Attack Surface Management and Continuous Automated Red Teaming technology is informed by years of experience compromising some of the world’s most targeted organisations and utilised by Fortune 500, financial services and critical infrastructure providers every day.
Photo – https://mma.prnewswire.com/media/2401497/watchTowr_JupiterOne.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jupiterone-and-watchtowr-announce-partnership-to-protect-business-critical-assets-with-broad-exposure-management-capabilities-302132392.html

Continue Reading

Artificial Intelligence

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Published

on

clarivate-declares-dividend-on-mandatory-convertible-preferred-shares

LONDON, May 1, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT; CLVT PR A) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the “Preferred Shares”), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.

On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price (“VWAP”) of Clarivate’s ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the “valuation period”). If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share. The mandatory conversion rate will be announced following the end of the valuation period. The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the “Statement of Rights” for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate’s annual report on Form 10-K for the fiscal year ended December 31, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clarivate-declares-dividend-on-mandatory-convertible-preferred-shares-302133633.html

Continue Reading

Trending